Financial Performance - The company's revenue for Q3 2024 reached ¥166,614,606.37, representing a 77.84% increase compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥1,731,970.15, a 121.13% increase year-over-year[2]. - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥2,550,937.09, up 132.32% from the previous year[2]. - The company's basic earnings per share for Q3 2024 was ¥0.02, a 121.28% increase compared to the same period last year[2]. - Total revenue for Q3 2024 reached ¥484,361,918.38, an increase of 36% compared to ¥356,117,455.91 in the same period last year[14]. - The company's net profit for Q3 2024 was CNY 23,422,880.63, an increase from CNY 20,063,872.53 in the same period last year, representing a growth of approximately 11.8%[15]. - Basic and diluted earnings per share for Q3 2024 were both CNY 0.32, up from CNY 0.27 in the previous year, indicating a 18.5% increase[16]. - The total profit for Q3 2024 was CNY 25,370,269.31, compared to CNY 24,036,180.98 in the same period last year, showing an increase of 5.5%[15]. - The company reported a total comprehensive income of CNY 23,422,880.63 for Q3 2024, compared to CNY 20,063,872.53 in the previous year[15]. Cash Flow and Investments - Cash flow from operating activities for the year-to-date period reached ¥22,393,241.08, showing a 46.06% increase year-over-year[2]. - Cash flow from operating activities for Q3 2024 was CNY 22,393,241.08, compared to CNY 15,331,465.02 in Q3 2023, reflecting a growth of 46.1%[17]. - Total cash inflow from investment activities was CNY 1,717,308,599.97, significantly higher than CNY 50,127,191.63 in the previous year[17]. - Cash outflow from investment activities reached CNY 2,019,875,967.69, compared to CNY 669,219,381.10 in the same period last year, indicating a substantial increase in investment[18]. - The net cash flow from financing activities was CNY 30,678,128.48, a decrease from CNY 771,681,744.10 in Q3 2023[18]. Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥1,905,327,998.30, reflecting a 4.05% increase from the end of the previous year[2]. - The company's total liabilities decreased by 54.53% for current non-current liabilities due to reduced long-term borrowings[5]. - Total assets grew to ¥1,905,327,998.30 from ¥1,831,102,296.46, reflecting overall company growth[12]. - Short-term borrowings decreased to ¥192,383,421.61 from ¥217,337,131.55, indicating improved debt management[12]. - The total equity attributable to shareholders rose to ¥1,311,053,587.73 from ¥1,285,628,071.26, reflecting a solid financial position[13]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,888, with the top 10 shareholders holding 84.63% of the shares[7]. - Cai Danqun holds 34.89% of the shares, amounting to 25,820,000 shares, while Cai Shaoxin holds 21.19% with 15,680,000 shares[7]. - The total number of restricted shares at the beginning of the period was 56,051,236, with 9,551,236 shares released during the period, leaving 46,500,000 restricted shares at the end[9]. - The company has no new restricted shares added during the reporting period[9]. - The top shareholder, Cai Danqun, has a lock-up period until December 28, 2026, for his 25,820,000 shares[9]. - The company has a significant presence of institutional investors, with several private equity funds among the top shareholders[8]. - The largest single block of shares held by a fund is 4,200,000 shares, representing 5.68% of the total shares[7]. - The company has not reported any changes in the participation of the top shareholders in margin financing or securities lending activities[9]. - The company’s major shareholders have signed a concerted action agreement, indicating a unified control structure[8]. - The next scheduled release of restricted shares for several major shareholders is on June 27, 2024[9]. Research and Development - The company reported a significant increase in R&D expenses, which rose by 63.21% to ¥2,767.87[6]. - Research and development expenses amounted to ¥27,678,651.99, a 63% increase from ¥16,959,260.69 in the previous year, indicating a strong focus on innovation[14].
广康生化(300804) - 2024 Q3 - 季度财报